Calidi Biotherapeutics Inc. (NYSE American: CLDI) Focuses Innovation on Hard-to-Treat Tumors
As cancer numbers grow, Calidi Biotherapeutics is at the forefront of developing novel treatments aimed at improving patient outcomes. Calidi’s platform centers on the use of antitumor virotherapies that selectively infect and kill cancer cells while activating the body’s own immune system to attack the tumor. The company’s therapeutic pipeline targets multiple cancer indications, with a focus on hard-to-treat tumors. Cancer remains a significant global health challenge, with certain types exhibiting particularly high mortality rates. Glioblastoma multiforme (“GBM”), triple-negative breast cancer (“TNBC”), sarcoma and lung cancer are among the most aggressive and deadly forms, necessitating urgent advancements in research and…